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Introduction
IL-21 is a pleiotropic cytokine belonging to the common cytokine receptor g chain family of cytokines.
1-3 IL-21 is mainly produced by activated CD4
þ T cells and acts on T-, B-, NK-cells and other lineages. [3] [4] [5] IL-21 has a critical role in Ig production 6 and the lack of both IL-21 and IL-4 signals impairs normal germinal center formation. 6 Antitumor effects of IL-21 have been reported [7] [8] [9] with ongoing clinical trials. [10] [11] [12] [13] Moreover, IL-21 can drive Th17 differentiation.
14-16 IL-21 also contributes to the development of autoimmune disease as has been reported in mouse models, [17] [18] [19] [20] which is possibly related to Th17 differentiation.
GVHD is one of the major complications after hematopoietic SCT and the same graft simultaneously induces the graftversus-leukemia (GVL) effect, which reduces the relapse rate. In clinical practice, there is no GVHD-specific treatment, and all currently available immunosuppressive reagents attenuate GVL effect as well as GVHD. In mouse models, possible strategies were reported to specifically suppress GVHD, [21] [22] [23] [24] [25] [26] [27] [28] but nothing is available in the clinical setting at this point.
Previously, we have shown that IL-21R À/À (KO) splenocytes ameliorate GVHD as compared with wild-type splenocytes, 29 indicating a critical role of IL-21 in GVHD. Bucher et al. reported that IL-21 neutralization resulted in the same results as ours and they found that it did not attenuate GVL effect. 30 However, they did not titrate the required T-cells for GVL effect, making it impossible to determine if the GVL strength was similar in the normal and the IL-21-neutralized conditions. Here, we sought to quantify and compare the strength of GVL effect between WT and KO splenocytes, and moreover, to analyze the contributions of CD4 and CD8 cells to GVL effect.
Materials and methods

Mice
IL-21R
À/À (KO) mice were generated previously 6 and mice were C57BL/6 background. 29 IL-21R þ / þ (WT) mice were interbred progeny from the same littermate. C57BL/6-DBA2-F1 mice were purchased from Clea Japan (Tokyo, Japan). All mice used were 6-12 weeks old and housed in a small animal facility in Jichi Medical University, which is regulated by an intramural small animal committee, and were treated in accordance with the Jichi Medical University guidelines. ).
GVL models
31
CD8
þ T cell depletion from splenocytes was performed using CD8 magnetic-microbeads and an autoMACS (Miltenyi Biotech). The average proportion of CD8 þ T cells in spleen was 12-13% and after purification it declined to 3.4-3.6% in average. CD8 þ T cell purification from splenocytes was performed as above, not with negative selection but with positive selection. The purity was B85%. 51 Cr release assays (cytotoxic T cell lysis assays) As previously described, 21 T cells were purified with CD90 microbeads (Miltenyi Biotech) from splenocytes of C57BL/ 6-DBA-F1 recipient mice 14 days after BMT, and T cells from three mice were combined in each group. The percentage of CD8 Cr in the supernatants after incubation was determined using LumaPlate-96 and TopCount NXT (PerkinElmer, Boston, MA, USA).
MLR and ELISA T cells and CD8
þ T cells were purified using CD90 and CD8 microbeads (Miltenyi Biotech), and 1 Â 10 5 cells were cocultured with 30 Gy irradiated splenocytes (1 Â 10 5 ) from either C57BL/6-DBA2-F1 or C57BL/6 mice, as allogeneic or syngeneic stimulator in U-bottom 96-well plates. Culture medium was the same as described previously. 32 After 6 days of culture, concentrations of interferon-g and tumor necrosis factor a in the supernatants were determined by ELISA (BD Biosciences-Pharmingen, San Diego, CA, USA) as per the manufacturer's instructions.
Flow cytometric analysis
Fc-block (BD Biosciences-Pharmingen) was used to prevent nonspecific Ab binding to Fc receptors. Anti-CD4, CD8, H-2 b and H-2 d antibodies were purchased from BD Biosciences-Pharmingen. An LSR flow cytometer (BD Biosciences-Immunocytometry Systems, San Jose, CA, USA) was used for data collection, and the data were analyzed using CellQuest software (BD Biosciences-Immunocytometry Systems).
Decoy receptor of IL-21
We used the retrovirus-vector previously described. 29 Briefly, the primers, 5
0 -TTCTAGCTACCAGCTGCAGG T-3 0 and 5 0 -TCCTGAAGTTCCTCATATTCA-3 0 , were used to produce a truncated IL-21R lacking the region from box 1 to the C-terminus. 5, 29 Cell surface expression of this truncated receptor was confirmed by flow cytometric analysis using anti-IL-21-receptor polyclonal Ab (R&D Systems, Minneapolis, MN, USA) and a secondary Ab conjugated with PE (R&D Systems).
Retrovirus-mediated transduction into BM
A retrovirus construct containing p185 bcr-abl or the decoy IL-21R was transfected into the packaging cell line, PLAT-E, and the produced viruses were transduced into prestimulated BM using Retronectin according to the manufacturer's instructions (Takara, Osaka, Japan).
In vivo imaging
Luciferase gene was transduced into the P815 cell line using a lentiviral vector, which also includes modified green fluorescent protein gene. Green fluorescent protein-positive cells were purified using FACS sorter, FACSAria CellSorting System, (BD Biosciences, San Jose, CA, USA). At indicated time points, after transplantation, 3 mg of luciferin, a substrate of luciferase, was injected into mice i.v. Detection was performed with IVIS imaging system (Xenogen, Alameda, CA, USA) and the strength of light was measured by analyzing software 'Living ImageR ver2.5' (Xenogen).
Statistical analysis
Kaplan-Meier plots were used to compare survival rates. The Logrank test was used to evaluate P-values. Statistical analyses were performed using 'Stat Mate ver. 6' (ATMS, Tokyo, Japan). Unless otherwise specified, all error bars in this study are s.d.
Results
KO-SP retained GVL effect against P815 leukemic cell line
To evaluate the potential clinical utility of IL-21, we wished to determine whether the loss of an IL-21 signal abolished the GVL effect. To this end, we transplanted T-cell depleted wild-type BM cells together with P815 leukemic cells (H-2 d , DBA2 mouse derived) into recipient C57BL/6-DBA2 F1 mice. Only mice transplanted with splenocytes survived beyond 4 weeks, suggesting that the leukemic cells were eliminated by either WT-SP or KO-SP ( Figure 1 ). KO-SP-transplanted mice survived longer than WT-SPtransplanted mice ( Figure 1 ). The transplanted mice without splenocytes died within 4 weeks, all with paralyzed hind legs, and almost half with leukemic nodules on the liver. In contrast, the mice with probable GVHD did not show such phenotypes and suffered from diarrhea, ruffled hair, a hunched posture and weight loss. GVHD appeared to be the cause of death for these mice. Our previous results 29 suggest that the worse survival of recipients of WT-SP is because of GVHD.
IL-21 decoy receptor retained GVL effect against P815 cell line
To confirm these results, we used a previously constructed decoy receptor for IL-21, 29 in which the major cytoplasmic domain encompassing from box 1 through C-terminus was deleted. Theoretically, it can bind to IL-21 ligand but cannot evoke signals from the receptor, and in fact, the decoy receptor was shown to attenuate GVHD in the previous study. 29 To confirm that the decoy receptor does not abrogate the GVL effect analogous to KO-SP, we performed GVL experiments with P815 leukemic cells. As shown in Figure 2 , P815 efficiently killed recipient mice without splenocytes as in Figure 1 , and the decoy receptor transduced BM prolongs survival, suggesting that the blockade of IL-21 signal retains GVL effect.
IL-21R
À/À splenocyte retained GVL effect against bcr/ abl-transformed recipient-BM cells To further confirm the above results, we used another leukemic model, bcr-abl-transduced recipient-BM, instead of the established P815 leukemic cell line. Consistent with the results above, KO-SP-transplanted mice survived longer than WT-SP-transplanted mice (Figure 3a ). In this model, 2 weeks after transplantation, peripheral blood cells , suggesting the proliferation of bcr-abl-transduced recipient BM-derived leukemic cells. All mice we analyzed demonstrated the same pattern in peripheral blood. These results together with transplantation with P815 leukemic cells suggest that the lack of IL-21 signaling does not abolish the GVL effect. In this model, we found late relapse, suggesting that the GVL effect might not be sustained (Figure 3a , KO-SP).
Dose-reduction experiment with luciferase-expressing P815 leukemic cell line We decided to perform dose-response experiments to determine the number of splenocytes required to eliminate leukemic cells after transplantation, as otherwise it is impossible to compare the strength of GVL effect between the WT and KO cells. To make the leukemia visible in live mice, we used luciferase-transduced P815 cell line and IVIS imaging system (Xenogen). With this system, we could see GVL effect in color (Figure 4 ). We started with 1 Â ¼ 14) , respectively. The combined results of two independent experiments are shown. P-value was calculated by the Log-rank method. , regardless of genotype of IL-21R.
IL-21 and GVL
CD8-depleted grafts showed attenuated GVL effect Our previous experiments demonstrated that IL-21R
À/À
CD4
þ T cells are defective in GVH reactivity after transplantation. 32 It was therefore of great interest to determine whether IL-21R À/À CD4 þ T cells are also defective in GVL effect. To evaluate the contribution of CD4 þ T cells to GVL effect, we performed transplantation with CD8-depleted splenocytes with dose reduction as above. As CD8 T cells compose only B10% of splenocyte, we chose CD8-depletion rather than CD4 purification, so we could use the same dose of CD8-depleted splenocytes as in the case of bulk splenocytes. As shown in Figure 6 , CD8-depleted KO-SP at the dose of 5 Â 10 7 demonstrated attenuated GVHD and prolonged survival (top left panel), consistent with our previous experiments above 29 ( Figure 1 ). 
Control: SP(-)
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CD8-purified grafts did not show significant reduction in GVL effect
To further evaluate the contribution of CD8 þ T cells to GVL effect, we performed transplantation with CD8-purified splenocytes with dose reduction as above. As shown in Figure 7a , CD8-purified KO-SP at the dose of 5 Â 10 5 did not demonstrate a significant increase in the incidence of leukemic cell death (P ¼ 0.1), but if anything, CD8-purified KO-SP might have a slight decrease in GVL effect (lower left panel). Consistent with the survival, both CD8-purified KO-SP and WT-SP showed increased luciferase activity at day 21 (lower right panel). To confirm these results, we performed standard cytotoxic T cell assay using 51 Cr. Splenocytes from recipients of C57BL/6-DBA-2-F1 mice demonstrated similar and comparable killing activity (Figure 7b ). Cytokine production, at least, interferon-g from T cell and CD8 þ T cell in MLR was comparable between KO and WT (Supplementary Figure S1) .
Discussion
Here, we demonstrated that KO-SP, which ameliorate GVHD, do not attenuate graft-versus-leukemia (GVL) effect even in the splenocyte-dose titration. In the further detailed analysis with CD8-depleted and CD8-purified splenocytes, GVL effect with IL-21R À/À CD8-depleted splenocytes but not CD8-purified splenocytes was significantly diminished compared with wild type, suggesting that IL-21R À/À CD4 cells have lower GVL activity than wildtype cells but IL-21R À/À CD8 cells have no or only a tiny decrease in GVL effect. These results suggested that no reduction in the GVL effect with bulk splenocytes was because of a compensatory effect of IL-21R À/À CD8 cells on GVL effect. This conclusion is reasonable in view of the fact that IL-21R À/À CD4 cells or splenocytes induce less severe GVHD. 29, 32 As no immunosuppressive reagent specific for GVHD but not GVL effect is clinically available, the specific suppression of GVHD in the presence of both CD4 and CD8 cells is of interest and could contribute to the development of GVHD treatment.
During this manuscript preparation, Bucher et al. reported similar results 30 with our present and published data. 29, 32 The authors concluded that the GVL effect was maintained even after IL-21 neutralization, however, we believe that titration experiments are required in order to determine if GVL strength is the same between normal and IL-21 neutralized conditions, because the threshold of the required number of T-cells for GVL is much less than for GVHD, as we have shown in this study. One must titrate the dose of splenocytes to compare the GVL strength between the two groups, but this was not done by Bucher et al. ). Then, the dose of CD8-depleted splenocytes was reduced to 5 Â 10 6 and 5 Â 10 5 , gradually. Open squares, filled squares and filled triangles indicate transplantations without splenocytes, with WT-SP and KO-SP, respectively. Right panels indicate the average of signal intensity of luminescence in survivors at indicated days after transplantation, which correlates with leukemic-tumor-burden. Empirically determined positive-negative threshold indicated in broken line was 10 6 relative signal intensity per mouse.
We found that there were different thresholds and time frames between GVHD and GVL. Under our experimental conditions, 5 Â 10 6 bulk splenocytes did not induce death from GVHD but the dose can completely eliminate P815 leukemic cells. Thus, the required number of splenocytes was apparently less for the GVL effect than for GVHD. As we have shown, timings of GVHD and GVL effects appeared to be different. At 2 weeks after transplantation, leukemic cells in peripheral blood had been already eradicated (Figure 3 ) but symptoms of GVHD only became clinically obvious 3-4 weeks after transplantation. Our previous study demonstrated that CD4 dysfunction occurs only after transplantation, 32 suggesting the possibility that in the very early phase of GVHD, T cells still have normal GVL capacity to eliminate leukemic cells but GVL capacity gradually diminishes later on. However, our present study revealed that the incidence of leukemia was higher in the KO group than in the WT group at day 21 at the dose of 5 Â 10 6 CD8-depleted splenocytes. This experiment was performed with the same dose and analyzed at the same time point, suggesting that the cause of the diminished GVL effect may be CD4 dysfunction itself rather than differences in dose and timing.
In summary, our results revealed the attenuated GVL effect of IL-21R À/À splenocytes in the absence of CD8 T cells, whereas bulk splenocytes and CD8-purified splenocytes did not demonstrate such a defect, together indicating the importance of CD8 T cells for the effect. Our detailed analysis provides new insights regarding the role for IL-21 in GVL effect. 
